MYO6 Gene Deafness autosomal dominant type 22 Genetic Test
At DNA Labs UAE, we offer the MYO6 Gene Deafness autosomal dominant type 22 Genetic Test to help diagnose and manage progressive hearing loss. This genetic disorder is caused by mutations in the MYO6 gene, which affects the function of sensory hair cells in the inner ear.
Test Details
Deafness, autosomal dominant type 22 (DFNA22) is a genetic disorder characterized by progressive hearing loss. It is caused by mutations in the MYO6 gene. The MYO6 gene provides instructions for making a protein called myosin VI, which is involved in the movement and organization of cells. In the inner ear, myosin VI is essential for the proper function of sensory hair cells, which are responsible for converting sound vibrations into electrical signals that can be interpreted by the brain.
Mutations in the MYO6 gene disrupt the normal function of myosin VI, leading to the degeneration and loss of sensory hair cells in the inner ear. This results in progressive hearing loss, typically starting in late childhood or early adulthood.
To diagnose DFNA22, a next-generation sequencing (NGS) genetic test can be performed. NGS allows for the simultaneous sequencing of multiple genes, including MYO6, to identify any disease-causing mutations. During the test, a sample of DNA is obtained, usually through a blood sample, and then sequenced using NGS technology. The DNA sequence data is analyzed, and any mutations or variations in the MYO6 gene are identified. If a disease-causing mutation is found, it confirms the diagnosis of DFNA22.
NGS genetic testing for DFNA22 can be helpful in identifying individuals at risk for the condition, providing a definitive diagnosis, and guiding appropriate management and treatment strategies. It can also be used for genetic counseling and family planning purposes.
Test Information
- Test Name: MYO6 Gene Deafness autosomal dominant type 22 Genetic Test
- Components: Blood or Extracted DNA or One drop Blood on FTA Card
- Price: 4400.0 AED
- Report Delivery: 3 to 4 Weeks
- Method: NGS Technology
- Test Type: Ear Nose Throat Disorders
- Doctor: ENT Doctor
- Test Department: Genetics
- Pre Test Information: Clinical History of Patient who is going for SLC52A3 Gene Brown-Vialetto-Van Laere syndrome 1 NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with SLC52A3 Gene Brown-Vialetto-Van Laere syndrome 1 NGS Genetic DNA Test gene SLC52A5
It is important to consult with a healthcare professional or a genetic counselor to discuss the specific details and implications of the MYO6 gene NGS genetic test in the context of deafness, autosomal dominant type 22.
| Test Name | MYO6 Gene Deafness autosomal dominant type 22 Genetic Test |
|---|---|
| Components | |
| Price | 4400.0 AED |
| Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card |
| Report Delivery | 3 to 4 Weeks |
| Method | NGS Technology |
| Test type | Ear Nose Throat Disorders |
| Doctor | ENT Doctor |
| Test Department: | Genetics |
| Pre Test Information | Clinical History of Patient who is going for SLC52A3 Gene Brown-Vialetto-Van Laere syndrome 1 NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with SLC52A3 Gene Brown-Vialetto-Van Laere syndrome 1 NGS Genetic DNA Test gene SLC52A5 |
| Test Details |
Deafness, autosomal dominant type 22 (DFNA22) is a genetic disorder characterized by progressive hearing loss. It is caused by mutations in the MYO6 gene. The MYO6 gene provides instructions for making a protein called myosin VI, which is involved in the movement and organization of cells. In the inner ear, myosin VI is essential for the proper function of sensory hair cells, which are responsible for converting sound vibrations into electrical signals that can be interpreted by the brain. Mutations in the MYO6 gene disrupt the normal function of myosin VI, leading to the degeneration and loss of sensory hair cells in the inner ear. This results in progressive hearing loss, typically starting in late childhood or early adulthood. To diagnose DFNA22, a next-generation sequencing (NGS) genetic test can be performed. NGS allows for the simultaneous sequencing of multiple genes, including MYO6, to identify any disease-causing mutations. During the test, a sample of DNA is obtained, usually through a blood sample, and then sequenced using NGS technology. The DNA sequence data is analyzed, and any mutations or variations in the MYO6 gene are identified. If a disease-causing mutation is found, it confirms the diagnosis of DFNA22. NGS genetic testing for DFNA22 can be helpful in identifying individuals at risk for the condition, providing a definitive diagnosis, and guiding appropriate management and treatment strategies. It can also be used for genetic counseling and family planning purposes. It is important to consult with a healthcare professional or a genetic counselor to discuss the specific details and implications of the MYO6 gene NGS genetic test in the context of deafness, autosomal dominant type 22. |
